COMMUNIQUÉS West-GlobeNewswire

Pédalons pour la cause : la Jack Ride mobilise le pays pour la santé mentale des jeunes

12/02/2025 - 15:00

Rejoignez les milliers de Canadien.ne.s qui se mobilisent pour offrir espoir et soutien à la jeunesse LÉGENDE : Des centaines de participant.e.s qui unissent leurs efforts lors de la Jack Ride pour financer des [...]

Pedal for Progress with Jack Ride: Canadians Ride for Youth Mental Health

12/02/2025 - 15:00

Join tens of thousands of Jack.org supporters to raise hope and funds together CAPTION: Hundreds come together for Jack Ride to support programs equipping youth with vital mental health education TORONTO, Feb. 12, 2025 [...]

Board member Roland Norberg requests to resign from the Board

12/02/2025 - 16:00

Aino Health AB's board member Roland Norberg has today, 12 February 2025, requested to resign from the company's board. The reason for the resignation is that the company that nominated Roland Norberg, Norberg & [...]

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

12/02/2025 - 16:43

Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart [...]

Tanke Biosciences Corp Announces Appointment of Vincent Renz as Chief Executive Officer and Member of the Board of Directors

12/02/2025 - 17:00

Las Vegas, NV, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Tanke Biosciences Corp (the “Company”) (OTC: TNBI) announced today that Vincent Renz has been appointed Chief Executive Officer and will join the Board of Directors, [...]

Genmab Publishes 2024 Annual Report

12/02/2025 - 17:01

Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial [...]

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

12/02/2025 - 17:02

ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 [...]

Legend Senior Living® Expands with New Residence in King of Prussia

12/02/2025 - 17:19

PHILADELPHIA, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a national senior living provider headquartered in Wichita, KS, is partnering in the new ownership and will operate Anthology Living in King of [...]

FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

12/02/2025 - 17:45

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the [...]

EssilorLuxottica: Résultats T4 et annuels 2024 - Solide croissance du chiffre d’affaires et augmentation de la marge en 2024. Un nouveau vecteur de croissance : les lunettes connectées, débuts prometteurs de Nuance Audio

12/02/2025 - 18:00

Solide croissance du chiffre d’affaires et augmentation de la marge en 2024 Un nouveau vecteur de croissance : les lunettes connectées, débuts prometteurs de Nuance Audio Hausse de +9,2 % du chiffre d'affaires du Groupe [...]

EssilorLuxottica: Q4/FY 2024 Results - Sound sales growth and margin expansion in 2024. Smartglasses as a new driver, Nuance off to a promising start

12/02/2025 - 18:00

Sound sales growth and margin expansion in 2024 Smartglasses as a new driver, Nuance off to a promising start Group revenue at constant exchange rates 1 +9.2% in Q4 and +6.0% in the FY North America accelerating in Q4, [...]

SAFE GROUP - CHIFFRE D’AFFAIRES 2024

12/02/2025 - 18:34

CHIFFRE D’AFFAIRES 2024 Fleurieux-sur-l’Arbresle - France - le 12 février 2025 à 18h30. Safe Group publie son chiffre d’affaires annuel consolidé réalisé sur l’exercice 2024. En K€ 2024 (1) 2023 (2) Variation en % [...]

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

12/02/2025 - 19:00

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

12/02/2025 - 19:14

Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial [...]

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

12/02/2025 - 20:00

ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 12 FEBRUARY 2025 at 21.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

12/02/2025 - 20:45

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in [...]

Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26

12/02/2025 - 22:00

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH), a leading precision [...]

atai Life Sciences Announces Proposed Public Offering of Common Shares

12/02/2025 - 22:01

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders [...]

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

12/02/2025 - 22:01

– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon ™ CNP NDA for [...]